Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0VYKSA)
| ADC Name |
Vemzatatug vedotin
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
LM-305; AZD0305
Click to Show/Hide
|
|||||
| Organization |
LaNova Medicines (Originator);AstraZeneca (Top20 MNC)
|
|||||
| Drug Status |
Phase 1/2
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Structure |
|
|||||
| Antibody Name |
Anti-GPRC5D antibody
|
Antibody Info | ||||
| Antigen Name |
G-protein coupled receptor family C group 5 member D (GPRC5D)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Payload Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
| Combination Type |
vedotin
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Indication | Phase 1 | Phase 2 | Phase 3 | Approved | |||
|---|---|---|---|---|---|---|---|
| Multiple myeloma |
2 Trials
|
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Discovered Using Cell Line-derived Xenograft Model
| Standard Type | Value | Units | Cell Line | Disease Model |
|---|---|---|---|---|
| Tumor Growth Inhibition value (TGI) |
≈ 100
|
%
|
Multiple myeloma cells
|
Multiple myeloma
|
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Key inclusion criteria: signed ICF; age ≥18; ECOG 0-1; life expectancy ≥6 months; adequate hematologic/organ function (specific laboratory thresholds to be confirmed per protocol).
|
||||
| Administration Dosage |
LM-305 Dose Escalation
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT05647512 | Clinical Status | PHASE1|||PHASE2 | ||
| Clinical Description | A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases | ||||
| Primary Endpoint |
Primary safety endpoints include dose-limiting toxicity (DLT) assessment during Cycle 1 (21-day cycle) and comprehensive AE/SAE monitoring from ICF signing until 28 days post-EOT or alternative anticancer therapy initiation to evaluate LM-305 safety profile.
|
||||
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100% | High GPRC5D expression (GPRC5D+++) | ||
| Method Description |
The inhibitory activity of LM-305 against cancer cell growth was evaluated in Multiple myeloma CDX model in vivo. The dose of LM-305 was 3 mg/kg.
|
||||
| In Vivo Model | Multiple myeloma CDX model | ||||
| In Vitro Model | Multiple myeloma | Multiple myeloma cells | Homo sapiens | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.10-0.30 nM | High GPRC5D expression (GPRC5D+++) | ||
| Method Description |
LM-305 was evaluated in vitro for its cytotoxic activity against a panel of multiple myeloma cell lines. LM-305 was co-cultured with multiple myeloma cells.
|
||||
| In Vitro Model | Plasma cell myeloma | MM1.R cells | CVCL_8794 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.10-0.30 nM | High GPRC5D expression (GPRC5D+++) | ||
| Method Description |
LM-305 was evaluated in vitro for its cytotoxic activity against a panel of multiple myeloma cell lines. LM-305 was co-cultured with multiple myeloma cells.
|
||||
| In Vitro Model | Plasma cell myeloma | NCI-H929 cells | CVCL_1600 | ||
References